Four insights:
1. The company’s partner, Sioux Falls, S.D.-based Sanford Health, will contribute the additional funds, supporting InGeneron’s study in rotator cutoff tendinopathy and other programs in its autologous cell therapy line.
2. InGeneron’s therapeutic method isolates and prepares adipose-deprived regenerative cells from a patient’s fat tissue and administers the cells at the site of injury.
3. The company’s focus is on developing an autologous cell therapy to treat pain and impairments linked with musculoskeletal conditions.
4. InGeneron launched three clinical programs focusing on key musculoskeletal conditions, with its lead program in partial thickness rotator cutoffs currently enrolling patients in a double-blinded study.
“This is an exciting time for the company, as one of the largest health systems in the United States further affirms the potential of adipose-derived regenerative cell therapy, while we diligently work to make it available to patients,” said Engelo Moesslang, PhD, CEO of InGeneron.
More articles on biologics:
Ossio wins Frost & Sullivan award for bone regeneration technology — 4 insights
Konica Minolta Healthcare partners with EmCyte in biologics workshop
Bioventus collaborates with MTF Biologics in tissue product for knee osteoarthritis
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
